Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 9/20 | 1.00 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.64 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | CES2 | O00748 | 1/20 | 0.54 |
| ▸ | CES1 | P23141 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylsulfanylmethane SCHEMBL28782225 | 0.94 | GSK3B (0.88) | GSK3BPTPN1NPC1RAB9AKMT2A | |
| SCHEMBL8213015 | 0.94 | GSK3B (0.88) | GSK3BPTPN1NPC1RAB9AKMT2A | |
| SCHEMBL205280 | 0.87 | GSK3B (0.80) | GSK3BPTPN1NPC1RAB9A | |
| SCHEMBL10120374 | 0.85 | GSK3B (0.73) | GSK3BPTPN1NPC1RAB9AKMT2A | |
| Phenacyl Chloride SCHEMBL28106866 | 0.84 | GSK3B (0.70) | GSK3BPTPN1NPC1RAB9AKMT2A | |
| SCHEMBL11599481 | 0.83 | GSK3B (0.70) | GSK3BPTPN1NPC1RAB9AKMT2A | |
| SCHEMBL8107659 | 0.82 | GSK3B (0.68) | GSK3BPTPN1NPC1RAB9AKMT2A | |
| SCHEMBL25031526 | 0.82 | GSK3B (0.69) | GSK3BPTPN1NPC1RAB9AKMT2A | |
| SCHEMBL15199328 | 0.82 | GSK3B (0.69) | GSK3BNPC1RAB9AKMT2AMEN1 | |
| Benzonitrile SCHEMBL28107145 | 0.81 | GSK3B (0.70) | GSK3BPTPN1NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1438 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119930621-A | Fungus-inhibiting matrine hydrazine thiazole derivative and preparation method and application thereof | 南京林业大学 | 2025-05-06 | — | — | CN | claimed |
| CN-118930487-A | 1,3, 5-Trisubstituted pyrazole compound and preparation method thereof | 赣南师范大学 | 2024-11-12 | — | — | CN | claimed |
| CN-115557865-B | Thioether-promoted cysteine-based bioconjugate method | 南京工业大学 | 2024-05-14 | — | — | CN | claimed |
| EP-3959200-B1 | NEW TRIAZOLE AND TRIAZOLOTHIADIAZINE DERIVATIVES EXERTING CYTOTOXIC AND APOPTOTIC EFFECTS ON A549 CELLS THROUGH AKT INHIBITION | ANADOLU UNIV (TR) | 2024-03-20 | — | — | EP | claimed |
| EP-3958980-B1 | TARGETED NOVEL TRIAZOLOTHIADIAZINE DERIVATIVES FOR THE TREATMENT OF LUNG CANCER | ANADOLU UNIV (TR) | 2023-11-15 | — | — | EP | claimed |
| CN-116396245-A | Pleuromutilin derivatives and process for preparing same | 西北工业大学宁波研究院 | 2023-07-07 | — | — | CN | claimed |
| CN-115557865-A | Thioether-promoted cysteine-based bioconjugation method | 南京工业大学 | 2023-01-03 | — | — | CN | claimed |
| CN-114989175-A | Imidazopyrazine-containing compound and application thereof | 佛山市晨康生物科技有限公司 | 2022-09-02 | — | — | CN | claimed |
| EP-3958980-A1 | TARGETED NOVEL TRIAZOLOTHIADIAZINE DERIVATIVES FOR THE TREATMENT OF LUNG CANCER | Anadolu Universitesi (TR) | 2022-03-02 | — | — | EP | claimed |
| EP-3959200-A1 | NEW TRIAZOLE AND TRIAZOLOTHIADIAZINE DERIVATIVES EXERTING CYTOTOXIC AND APOPTOTIC EFFECTS ON A549 CELLS THROUGH AKT INHIBITION | Anadolu Universitesi (TR) | 2022-03-02 | — | — | EP | claimed |
| US-20080293947-A1 | Method of Preparation for Imidazolepyridines | MALLINCKRODT INC. | 2008-11-27 | — | — | US | claimed |
| EP-1966201-A1 | IMPROVED METHOD OF PREPARATION FOR IMIDAZOLEPYRIDINES | Mallinckrodt, Inc. (US) | 2008-09-10 | — | — | EP | claimed |
| WO-2007064444-A1 | IMPROVED METHOD OF PREPARATION FOR IMIDAZOLEPYRIDINES | MALLINCKRODT INC. (US) | 2007-06-07 | — | — | WO | claimed |
| JP-2006507350-A | — | — | 2006-03-02 | — | — | JP | claimed |
| CN-1741802-A | Propargyl-trifluoromethoxy-amino-benzothiazole derivatives | TEVA PHARMA (IL) | 2006-03-01 | — | — | CN | claimed |
| EP-1569641-A2 | PROPARGYL-TRIFLUOROMETHOXY-AMINO-BENZOTHIAZOLE DERIVATIVES | Teva Pharmaceutical Industries Limited (IL) | 2005-09-07 | — | — | EP | claimed |
| US-20040176430-A1 | Propargyl-trifluoromethoxy-amino-benzothiazole derivatives | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2004-09-09 | — | — | US | claimed |
| WO-2004047756-A2 | PROPARGYL-TRIFLUOROMETHOXY-AMINO-BENZOTHIAZOLE DERIVATIVES | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2004-06-10 | — | — | WO | claimed |
| US-3994772-A | KLEBSIELLA, A-BROMO-P-METHYLACETOPHENONE, 1,3-DICHLOROACETONE OXIME ACETATE | BETZ LABORATORIES, INC. (US) | 1976-11-30 | — | — | US | claimed |
| US-3989585-A | Synergistic compositions containing α-bromo-p-methylacetophenone and bis(trichloromethyl) sulfone and their use as slimicides | BETZ LABORATORIES, INC. (US) | 1976-11-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293947-A1 | Method of Preparation for Imidazolepyridines | ITPA, QDPR, NISCH | GSK3B 4451/4885PTPN1 3183/4885NPC1 4098/4885 |
| US-20040176430-A1 | Propargyl-trifluoromethoxy-amino-benzothiazole derivatives | CLIC1, CCR1, CCR4 | GSK3B 3302/4885PTPN1 640/4885NPC1 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.